This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.
Dr. Reddy's (RDY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fourth-quarter results where both earnings and revenues beat estimates.
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights Insperity, Microchip Technology, Darden Restaurants, Dr. Reddy's and W.W. Grainger
by Zacks Equity Research
Insperity, Microchip Technology, Darden Restaurants, Dr. Reddy's and W.W. Grainger have been highlighted in this Screen of The Week article.
5 Top-Ranked Dividend Growth Stocks to Buy Now
by Sweta Killa
Insperity (NSP), Microchip Technology (MCHP), Darden Restaurants (DRI), Dr. Reddys (RDY) and W.W. Grainger (GWW) could be compelling picks for investors.
Strength Seen in Amphastar (AMPH): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Amphastar (AMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
U.S. Economy Suffering From Dichotomy: 5 Safe Stocks
by Nalak Das
We have selected five defensive stocks with strong momentum. These are: CAG, COTY, NEE, NJR, RDY.
Zacks.com featured highlights include Dr. Reddys Laboratories, Darden Restaurants, The Interpublic Group of Companies, Microchip Technology and Valero Energy
by Zacks Equity Research
Dr. Reddys Laboratories, Darden Restaurants, The Interpublic Group of Companies, Microchip Technology and Valero Energy are part of the Zacks Screen of the Week article.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
by Zacks Equity Research
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
5 Top-Ranked Dividend Stocks to Counter Market Volatility
by Sweta Killa
Dr. Reddys (RDY), Darden Restaurants (DRI), Interpublic Group (IPG), Microchip Technology (MCHP) and Valero Energy (VLO) could be compelling picks amid market volatility.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Generic Drug Stocks to Watch Amid Macro Headwinds
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TEVA Shares Rise on Broad Support for Opioids Settlement
by Zacks Equity Research
With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.
New Strong Buy Stocks for January 10th
by Zacks Equity Research
STNE, JD, VSH, MOMO and RDY have been added to the Zacks Rank #1 (Strong Buy) List on January 10 , 2023.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Doctor Reddy's (RDY) have performed compared to their sector so far this year.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Jumps 5.5%: Will It Continue to Soar?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Doctor Reddy's (RDY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Doctor Reddy's (RDY) closed the most recent trading day at $52.12, moving +0.77% from the previous trading session.
The Zacks Analyst Blog Highlights JD.com, Sigma Lithium, Dr. Reddys Laboratories, MakeMyTrip and Coupang
by Zacks Equity Research
JD.com, Sigma Lithium, Dr. Reddys Laboratories, MakeMyTrip and Coupang are part of the Zacks top Analyst Blog.
5 Best Emerging Markets Stocks to Buy for 2023
by Urmimala Biswas
Here are five emerging market stocks, JD, SGML, RDY, MMYT and CPNG that are expected to gain enormously in 2023, capitalizing on their growth prospects.
Doctor Reddy's (RDY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Doctor Reddy's (RDY) closed at $52.85 in the latest trading session, marking a +0.3% move from the prior day.